
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lasofoxifene,Abemaciclib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sermonix Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : With the recent Health Canada agreement to proceed, the open-label, randomized Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1, NCT03781063) study will now include Exactis Network sites in Quebec, Ontario, Nova Scotia and New Brunswick.
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Undisclosed
September 30, 2020
Lead Product(s) : Lasofoxifene,Abemaciclib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sermonix Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
